Q3 2025 Orthofix Medical Inc Earnings Call Transcript

Nov 4, 2025 / 01:30 PM GMT

Release Date Price: $14.87 (-7.41%)

Transcript 10-Q8-K

Key Points

Positve

Orthofix Medical Inc (OFIX) achieved solid year-over-year and sequential revenue growth, particularly in the USA spine and orthopedics businesses.
The company marked its seventh consecutive quarter of adjusted EBITDA margin expansion and sustained positive free cash flow generation.
Net sales in the US spine fixation segment increased by 8%, with procedural volume up 10%, driven by the adoption of the 7D flash navigation system.
The TOP30 US distributor partners grew net sales by 25% year-over-year in Q3, validating the company's go-to-market strategy.
Orthofix Medical Inc (OFIX) reported a 19% growth in US orthopedics, marking the fifth consecutive quarter of double-digit growth.

Negative

The company experienced a price decrease at a major account, which partially offset the increased procedure volume in the US spine fixation segment.
International orthopedics grew only 1%, consistent with expectations but indicating variability in stocking distributor and tender order timing.
Despite strong Q3 performance, the guidance for Q4 implies a slight deceleration in growth to about 4% from 6% in Q3.
The company is facing challenges in maintaining gross margins due to unfavorable geography mix despite productivity improvements.
Orthofix Medical Inc (OFIX) is still in the process of consolidating distributor partners, which may present short-term disruptions.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

OFIX.OQ - Orthofix Medical Inc
Q3 2025 Orthofix Medical Inc Earnings Call
Nov 04, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Orthofix 3rd quarter 2025 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answers.

If you would like to ask a question during this time, simply press and the number one on your telephone keypad. To withdraw your question, press one again. We kindly ask that you please limit your questions to one and one related follow-up. I'd now like to turn the conference over to Julie Dewey. Please go ahead.

--------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.